Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Monoallelic Deletion of the Whole Locus of Immunoglobulin Heavy Chain Gene [Del(IGH)] Is Associated with a Better Prognosis in Newly Diagnosed Multiple Myeloma

Luba Trakhtenbrot, PhD, Adrian Duek, MD, Ninette Amariglio, PhD, Abraham Avigdor, MD, Noam Benyamini, MD, Izhar Hardan, MD, Itay Zilbershatz, MD, Chezi Ganzel, MD, Olga Shvetz, MD, Ronit Leiba, PhD, Marina Izak, MD, Cohen Ziv, Ba, Gabriela Rozic, PhD, Arnon Nagler, MD, Merav Leiba

Blood (2017) 130 (Supplement 1): 5368.

https://doi.org/10.1182/blood.V130.Suppl_1.5368.5368

Published: 2017

Journal Articles

Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials

Blood (2014) 124 (21): 198.

https://doi.org/10.1182/blood.V124.21.198.198

Published: 2014

Journal Articles

Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients

Blood (2013) 122 (21): 2089.

https://doi.org/10.1182/blood.V122.21.2089.2089

Published: 2013

Journal Articles

Outcomes of AL Amyloidosis Patients Treated with Novel Agents: A Collaborative Retrospective Multicenter Assessment

Moshe E. Gatt, MD, Izhar Hardan, MD, Evgene Chubar, MD, Celia Surio, Tamar Tadmor, MD, Olga Shvez, Paulina Patachenco, Najib Dali, MD, Shay Yeganeh, MD, Irit Avivi, MD

Blood (2012) 120 (21): 1860.

https://doi.org/10.1182/blood.V120.21.1860.1860

Published: 2012

Journal Articles

Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study

Blood (2011) 118 (21): 3069.

https://doi.org/10.1182/blood.V118.21.3069.3069

Published: 2011

Journal Articles

BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation

Arnon Nagler, M.D., Avichai Shimoni, Irit Avivi, Jacob M. Rowe, Katia Beider, Izhar Hardan, Michal Abraham, Hanna Wald, Eithan Galun, Howard Laurence Shaw, Orly Eizenberg, Amnon Peled

Blood (2010) 116 (21): 2260.

https://doi.org/10.1182/blood.V116.21.2260.2260

Published: 2010

Journal Articles

A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m 2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients

Blood (2010) 116 (21): 3573.

https://doi.org/10.1182/blood.V116.21.3573.3573

Published: 2010

Journal Articles

Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.

Avichai Shimoni, MD, Avital Rand, RN, BSN, Noga Shem-Tov, Izhar Hardan, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler, M.D.

Blood (2010) 116 (21): 3473.

https://doi.org/10.1182/blood.V116.21.3473.3473

Published: 2010

Journal Articles

Attempt to Discontinue Imatinib Following Interferon Alfa Pre-Treatment In Chronic Phase CML Patients Achieving Stable Complete Cytogentic Responses (CCyR)

Izhar Hardan, Yulia Volchek, MD, Tali Tohami, MD, PhD, Ninette Amariglio, Luba Trakhtenbrot, Maya Koren-Michowitz, Arnon Nagler, M.D.

Blood (2010) 116 (21): 4898.

https://doi.org/10.1182/blood.V116.21.4898.4898

Published: 2010

Journal Articles

Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation

Avichai Shimoni, MD, Avital Rand, RN, BSN, Noga Shem-Tov, MD, Izhar Hardan, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler, M.D.

Blood (2010) 116 (21): 2314.

https://doi.org/10.1182/blood.V116.21.2314.2314

Published: 2010

Journal Articles

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Avichai Shimoni, MD, Avital Rand, RN, Noga Shem-Tov, MD, Izhar Hardan, Yulia Volchek, MD, Hannah Maayaan, MD, Ronit Yerushalmi, Arnon Nagler, MD

Blood (2009) 114 (22): 2255.

https://doi.org/10.1182/blood.V114.22.2255.2255

Published: 2009

Journal Articles

Long-Term Survival and Late Events After Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning (RIC) for AML and Mds; Comparable Results with Myeloablative Conditioning.

Avichai Shimoni, Avital Rand, Noga Shem-Tov, Izhar Hardan, Yulia Volchek, Hannah Maayaan, Ronit Yerushalmi, Arnon Nagler

Blood (2009) 114 (22): 518.

https://doi.org/10.1182/blood.V114.22.518.518

Published: 2009

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine/Treosulfan Conditioning Regimen Compared with Busulfan-Based Myeloablative and Reduced-Intensity Conditioning in Patients with AML and Mds; Relative Outcomes Depend On Disease Status at Transplantation.

Avichai Shimoni, Avital Rand, Noga Shem-Tov, Izhar Hardan, Yulia Volchek, Hannah Maayaan, Ronit Yerushalmi, Arnon Nagler

Blood (2009) 114 (22): 3358.

https://doi.org/10.1182/blood.V114.22.3358.3358

Published: 2009

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with Refractory and Relapsing Multiple Myeloma: Long-Term Follow-up.

Avichai Shimoni, Izhar Hardan, Francis Ayuk, Georgia Schilling, Djordje Atanackovic, Wolfgang Zeller, Noga Shem-Tov, Avital Rand, Ronit Yerushalmi, Axel Zander, Nicolaus Kroger, Arnon Nagler

Blood (2009) 114 (22): 3359.

https://doi.org/10.1182/blood.V114.22.3359.3359

Published: 2009

Journal Articles

A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M 2 ) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis.

Blood (2009) 114 (22): 350.

https://doi.org/10.1182/blood.V114.22.350.350

Published: 2009

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Acute Lymphoblastic Leukemia: Better Outcome in Transplantation during First Complete Remission and with Myeloablative Conditioning

Avichai Shimoni, Avital Rand, Izhar Hardan, Noga Shem-Tov, Anfisa Stanevsky, Ronit Yerushalmi, Arnon Nagler

Blood (2008) 112 (11): 3295.

https://doi.org/10.1182/blood.V112.11.3295.3295

Published: 2008

Journal Articles

Isolated Extra-Medullary Relapse of Acute Leukemia after Allogeneic Stem-Cell Transplantation; Different Kinetics and Better Prognosis Than Systemic Relapse.

Avichai Shimoni, Avital Rand, Izhar Hardan, Noga Shem-Tov, Etai Zilbershatz, Ronit Yerushalmi, Arnon Nagler

Blood (2008) 112 (11): 2148.

https://doi.org/10.1182/blood.V112.11.2148.2148

Published: 2008

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: Long-Term Follow-up.

Avichai Shimoni, Avital Rand, Izhar Hardan, Noga Shem-Tov, Yulia Volchek, Ronit Yerushalmi, Arnon Nagler

Blood (2008) 112 (11): 2166.

https://doi.org/10.1182/blood.V112.11.2166.2166

Published: 2008

Journal Articles

Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.

Avichai Shimoni, MD, Izhar Hardan, MD, Avital Rand, RN, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 2002.

https://doi.org/10.1182/blood.V110.11.2002.2002

Published: 2007

Journal Articles

Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).

Avichai Shimoni, MD, Izhar Hardan, MD, Noga Shem-Tov, MD, Avital Rand, RN, Elena Ribakovsky, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 1650.

https://doi.org/10.1182/blood.V110.11.1650.1650

Published: 2007

NARROW

Monoallelic Deletion of the Whole Locus of Immunoglobulin Heavy Chain Gene [Del(IGH)] Is Associated with a Better Prognosis in Newly Diagnosed Multiple Myeloma

Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials

Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients

Outcomes of AL Amyloidosis Patients Treated with Novel Agents: A Collaborative Retrospective Multicenter Assessment

Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study

BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation

A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m 2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients

Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.

Attempt to Discontinue Imatinib Following Interferon Alfa Pre-Treatment In Chronic Phase CML Patients Achieving Stable Complete Cytogentic Responses (CCyR)

Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Long-Term Survival and Late Events After Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning (RIC) for AML and Mds; Comparable Results with Myeloablative Conditioning.

Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine/Treosulfan Conditioning Regimen Compared with Busulfan-Based Myeloablative and Reduced-Intensity Conditioning in Patients with AML and Mds; Relative Outcomes Depend On Disease Status at Transplantation.

Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with Refractory and Relapsing Multiple Myeloma: Long-Term Follow-up.

A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M 2 ) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis.

Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Acute Lymphoblastic Leukemia: Better Outcome in Transplantation during First Complete Remission and with Myeloablative Conditioning

Isolated Extra-Medullary Relapse of Acute Leukemia after Allogeneic Stem-Cell Transplantation; Different Kinetics and Better Prognosis Than Systemic Relapse.

Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: Long-Term Follow-up.

Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.

Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only